Meeting
2022 ASCO Annual Meeting
Efficacy and safety of NT-I7, long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: Results from the phase 2a study.
Presenter
Aung Naing, MD, FACP
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Clinical Trial Registration Number
NCT04332653
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2514)
DOI
10.1200/JCO.2022.40.16_suppl.2514
Abstract #
2514
Poster Bd #
170
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Annual Meeting
Safety and preliminary efficacy of EIK1001 in combination with pembrolizumab in participants with advanced solid tumors.
Speaker: Anthony W. Tolcher, MD, FASCO
Videos & Slides
2022 ASCO Annual Meeting
Interim safety and efficacy results from AURELIO-03: A phase 1 dose escalation study of the IL-2/IL-15 receptor βγ superagonist SOT101 as a single agent and in combination with pembrolizumab in patients with advanced solid tumors.
Speaker: Elena Garralda, MD, MSc
Videos & Slides
2021 ASCO Annual Meeting
BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.
Speaker: Manish R. Patel, MD
Videos & Slides
2024 ASCO Annual Meeting
Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (DEP CTX) in patients with advanced solid cancers in a phase 1/2 trial (P1/2).
Speaker: James F. Spicer, PhD, FRCP